• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis.

作者信息

Daungsupawong Hinpetch, Wiwanitkit Viroj

机构信息

Private Academic Consultant, Phonhong, Laos.

University Centre for Research and Development Department of Pharmaceutical Sciences, Chandigarh University Gharuan, Mohali, Punjab, India.

出版信息

Inflamm Bowel Dis. 2025 May 12;31(5):1487. doi: 10.1093/ibd/izae315.

DOI:10.1093/ibd/izae315
PMID:39743498
Abstract
摘要

相似文献

1
Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis.奥扎莫德和维多珠单抗作为溃疡性结肠炎的一线先进疗法
Inflamm Bowel Dis. 2025 May 12;31(5):1487. doi: 10.1093/ibd/izae315.
2
Comparative Effectiveness of Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis: A Propensity-Matched Cohort Analysis.奥扎莫德与维多珠单抗作为溃疡性结肠炎一线高级疗法的比较疗效：一项倾向匹配队列分析。
Inflamm Bowel Dis. 2024 Oct 30. doi: 10.1093/ibd/izae251.
3
Letter: Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis: Authors' Reply.信函：奥扎莫德和维多珠单抗作为溃疡性结肠炎的一线高级疗法：作者回复。
Inflamm Bowel Dis. 2025 May 12;31(5):1488. doi: 10.1093/ibd/izae304.
4
Comparative Speed of Early Symptomatic Remission With Advanced Therapies for Moderate-to-Severe Ulcerative Colitis: A Systematic Review and Network Meta-Analysis.比较中重度溃疡性结肠炎的早期症状缓解速度与先进治疗方法：系统评价和网络荟萃分析。
Am J Gastroenterol. 2023 Sep 1;118(9):1618-1625. doi: 10.14309/ajg.0000000000002263. Epub 2023 Mar 29.
5
Maintenance treatment with vedolizumab in paediatric inflammatory bowel disease (VEDOKIDS): 54-week outcomes of a multicentre, prospective, cohort study.维多珠单抗用于儿童炎症性肠病的维持治疗（VEDOKIDS）：一项多中心、前瞻性队列研究的54周结果
Lancet Gastroenterol Hepatol. 2025 Mar;10(3):234-247. doi: 10.1016/S2468-1253(24)00319-4. Epub 2025 Jan 6.
6
Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis.中重度溃疡性结肠炎治疗的新型疗法比较疗效：2024 年美国胃肠病学会证据综合报告
Gastroenterology. 2024 Dec;167(7):1460-1482. doi: 10.1053/j.gastro.2024.07.046. Epub 2024 Oct 18.
7
Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.生物制剂与口服小分子药物治疗炎症性肠病严重感染风险的比较：系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2023 Apr;21(4):907-921.e2. doi: 10.1016/j.cgh.2022.07.032. Epub 2022 Aug 6.
8
Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC).托法替布和维多珠单抗作为抗 TNF 药物治疗后溃疡性结肠炎二线治疗的真实疗效和安全性：一项多中心队列 IGIBD 研究（VE2TO-UC）
Dig Liver Dis. 2025 May 6. doi: 10.1016/j.dld.2025.04.025.
9
Long-Term Outcomes of an Infliximab-First Versus Vedolizumab-First Treatment Strategy in Biologic-Naïve Patients With Ulcerative Colitis.在初治的溃疡性结肠炎患者中，英夫利昔单抗优先与维多珠单抗优先治疗策略的长期结局
Aliment Pharmacol Ther. 2025 Feb;61(4):693-701. doi: 10.1111/apt.18441. Epub 2024 Dec 11.
10
Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.系统评价与网络荟萃分析：中重度溃疡性结肠炎的一线和二线药物治疗。
Aliment Pharmacol Ther. 2018 Jan;47(2):162-175. doi: 10.1111/apt.14422. Epub 2017 Dec 4.